VIMIAN GROUP AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.95 SEK | +4.46% |
|
+8.12% | +14.70% |
| May. 02 | Transcript : Vimian Group AB, Q1 2024 Earnings Call, May 02, 2024 | |
| May. 02 | Vimian Group AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 550.96 and 283.51 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 49 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +14.70% | 1.64B | - | ||
| -14.35% | 77.13B | B+ | ||
| +14.09% | 8.4B | B- | ||
| +27.62% | 3.79B | B- | ||
| -0.70% | 3.22B | B- | ||
| -10.12% | 1.5B | B | ||
| -22.60% | 1.3B | C- | ||
| -4.20% | 1.25B | - | ||
| -10.26% | 1.18B | - | ||
| +5.06% | 1.1B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VIMIAN Stock
- Ratings Vimian Group AB